Street Calls of the Week
DEERFIELD, Ill. - Baxter International Inc. (NYSE:BAX), an $11.2 billion market cap healthcare equipment manufacturer with annual revenues of $10.9 billion, has received a Gold Level Resiliency Badge from the Healthcare Industry Resilience Collaborative (HIRC) for its IV Solutions, Nutrition Solutions and Premix Drugs categories, according to a company press release. According to InvestingPro, Baxter remains a prominent player in the Healthcare Equipment & Supplies industry.
The medical technology company is the first manufacturer to earn this distinction across these specific product categories. The recognition follows HIRC’s evaluation of Baxter’s supply chain practices, including demand planning, logistics, and supplier partnerships. The company’s strong operational foundation is reflected in its healthy current ratio of 2.3, indicating robust short-term financial stability.
HIRC, a U.S. non-profit healthcare supply chain trade association founded in 2019, developed the badge as a tool to identify reliable suppliers through evidence-based assessments at the product category level.
"The HIRC Resiliency Badge is not about immunity to disruptions, but rather a supplier’s level of operational and risk management maturity to better predict, prevent, and recover from supply disruptions," said Jesse Schafer, HIRC’s executive director.
Baxter was recognized for strengths in several areas, including global logistics visibility, cybersecurity frameworks, risk management, inventory oversight, and continuous operational improvement.
The award builds on Baxter’s previous achievements, having earned HIRC’s Transparency Badge in both 2023 and 2024, which recognizes efforts to enhance visibility and business continuity planning.
Jim Borzi, Baxter’s executive vice president and chief supply chain officer, said the recognition validates the company’s "ongoing commitment to building a stronger, more transparent supply chain."
Baxter International develops and manufactures medical devices, with approximately 38,000 employees worldwide. The company has maintained dividend payments for 55 consecutive years, demonstrating long-term stability. Currently trading near its 52-week low, InvestingPro analysis suggests the stock is undervalued, with additional insights available in the comprehensive Pro Research Report, part of InvestingPro’s coverage of 1,400+ US equities.
In other recent news, Baxter International reported its financial results for the second quarter of 2025, missing earnings and revenue expectations. The company posted an earnings per share (EPS) of $0.59, slightly below the forecasted $0.61, which marked a 3.28% negative surprise. Revenue also fell short, coming in at $2.81 billion compared to the anticipated $2.82 billion. Additionally, Baxter International is facing a national security investigation initiated by the U.S. Commerce Department into medical equipment and devices. This probe has affected several major medical device manufacturers, including Baxter, with potential implications for the sector. The investigation is part of a Section 232 inquiry, which has created a new challenge for the industry, as noted by Needham. These developments highlight ongoing challenges for Baxter International and the broader medical device sector.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.